Comprehensive Pharmacogenetics (PGx) Gene Variation Panel
Pharmacogenetic testing is used to predict the responses to medications of patients using their genetic information. It combines patient genetic, pharmacological information, along with the clinic to help prevent serious adverse drug reactions (ADR). The medication selection guide and dosing for patients is given by the interpretation of genotype. US Food and Drug Administration (FDA) has approved many drug labels to include some pharmacogenetic information. Dosing Guidelines for more than 70 drugs have been published by the Clinical Pharmacogenetics Implementation Consortium and/or Royal Dutch Association for the Advancement of Pharmacy. In order to test for patient genetic information, an increasing number of pharmacogenetic tests are being developed as FDA-approved diagnostic tests. However, all in vitro pharmacogenetic tests are based on single gene or for single drug test. To get a comprehensive assessment and a more thorough understanding of patient genetic information, it will be necessary to test a combination of related genes that affect the patient medication.
Depending on laboratory panel design and patient population, Comprehensive Pharmacogenetics testing panel should include most relevant and most common genes covering more than 90% of the drugs utilized for patient care. Genes included in this panel are as follow: ABCB1, ABCG2, ADRA2A, ADRB2, ANKK1, COMT, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, CYP6A2, DPYD, DRD2, EPHX1, GIRK4, HTR1A, HTR2A, HTR2C, ITGB3, MFFI, NUDT, OPMR1, SLCO1B1, TPMT, UGT, VKORC1.
In addition, this comprehensive panel will include genetic variation of coagulation factors FV, FII and MTHFR used for thrombotic genetic risk evaluation as well as APOE genetic variation for arteriosclerosis and cardiovascular disease risk assessment and Alzheimer’s disease risk assessment. The genetic variations (mutations) of the above listed genes are tested using PCR based TaqMan® genotyping assay that uses PCR amplification and allele specific probe (ARMS) for mutation detection.
- Evaluation of drug therapy used for chronic diseases and disorders (long term therapy use) such as cardiovascular, psychotropic or mental illness, oncology and pain management
- Therapy selection and monitoring for chronic diseases and disorders (long term therapy use) such as cardiovascular, psychotropic or mental illness, oncology and pain management
See individual assay.
Whole blood (EDTA), buccal swab, saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Pharmacol Ther. 2013 Apr;138(1):103-41. [PMID: 23333322]
- Pharmacogenomics. 2019 Aug;20(13):971-982. [PMID: 31486733]
- Pain Physician. 2012 Jul;15(3 Suppl):S67-116. [PMID: 22786449]
- J Pers Med. 2021 Nov 11;11(11):1180. [PMID: 34834533]
- Adv Pharmacol. 2018;83:333-360. [PMID: 29801582]
- Pharmacol Rev. 2013 May 17;65(3):987-1009. [PMID: 23686351]
- Nature. 2015;526(7573):343–50. [PMID: 26469045]
- Drug Metab Pers Ther. 2016 Mar;31(1):25-34. [PMID: 26863347]
- Pharmacogenomics. 2020 Oct;21(15):1073-1084. [PMID: 33019866]
- Curr Pharm Des. 2010;16(2):155-63. [PMID: 20205661]
- Mol Oncol. 2012 Apr;6(2):251-9. [PMID: 22321460]
- Pharmacopsychiatry. 2021 Jan;54(1):5-17. [PMID: 33147643]
- Clin Pharmacol Ther. 2021 Sep;110(3):582-588. [PMID: 34129738]
- Genet Med. 2001 Mar-Apr;3(2):139-48. [PMID: 11280951]
- Genet Med. 2005 Jul-Aug;7(6):444-53. [PMID: 16024978]
- Arteriosclerosis. 1988 Jan-Feb;8(1):1-21. [PMID: 3277611]
- JAMA. 1994; 272(21):1666-71. [PMID: 7966894]
- Drug Metab Rev. 2009;41(2):89-295. [PMID: 19514967]
- Mol Psychiatry 2004;9:442-473. [PMID: 15037866]
- Mol Diagn Ther. 2013 Jun;17(3):165-84. [PMID: 23588782]
- Per Med. 2018 Mar;15(2):117-126 [PMID: 29714124]
- Pain Res Treat. 2013;2013:943014. [PMID: 24167729]
- Clin Biochem. 2014 Sep;47(13-14):1169-87. [PMID: 24912048]
- Biomarkers in medicine vol. 5,4 (2011): 427-38. [PMID: 21861665]
- Diseases. 2021 Aug 12;9(3):55. [PMID: 34449608]
- Human Cytochrome P450 (CYP) Allele Nomenclature Database. Available from URL: http://www.cypalleles.ki.se/cyp2d6.htm